These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38642125)

  • 1. Surgical management of rectal cancer with synchronous treatment of prostate cancer.
    Brière R; Martin AG; Letarte F; Fournier FR; Bouchard P; Drolet S
    Langenbecks Arch Surg; 2024 Apr; 409(1):133. PubMed ID: 38642125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical Management and Outcomes of Rectal Cancer with Synchronous Prostate Cancer: A Multicenter Experience from the GRECCAR Group.
    Doussot A; Vernerey D; Rullier E; Lefevre JH; Meillat H; Cotte E; Piessen G; Tuech JJ; Panis Y; Mege D; Meurisse A; De Bari B; Heyd B; Lakkis Z;
    Ann Surg Oncol; 2020 Oct; 27(11):4286-4293. PubMed ID: 32500342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The curative management of synchronous rectal and prostate cancer.
    Lavan NA; Kavanagh DO; Martin J; Small C; Joyce MR; Faul CM; Kelly PJ; O'Riordain M; Gillham CM; Armstrong JG; Salib O; McNamara DA; McVey G; O'Neill BD
    Br J Radiol; 2016; 89(1057):20150292. PubMed ID: 26539631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of total mesorectal excision (TME) surgery following dose-escalation: Surgical outcomes from the organ preservation in early rectal adenocarcinoma (OPERA) trial, a European multicentre phase 3 randomised trial (NCT02505750).
    Sun Myint A; Rao C; Barbet N; Thamphya B; Pace-Loscos T; Schiappa R; Magné N; Martel-Lafay I; Mineur L; Deberne M; Zilli T; Dhadda A; Gerard JP
    Colorectal Dis; 2023 Nov; 25(11):2160-2169. PubMed ID: 37837240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laparoscopic total mesorectal excision (TME) for rectal cancer surgery: long-term outcomes.
    Leroy J; Jamali F; Forbes L; Smith M; Rubino F; Mutter D; Marescaux J
    Surg Endosc; 2004 Feb; 18(2):281-9. PubMed ID: 14691716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium.
    Ishiyama H; Kamitani N; Kawamura H; Kato S; Aoki M; Kariya S; Matsumura T; Kaidu M; Yoshida K; Hashimoto Y; Noda Y; Lim KHC; Kawase T; Takahashi T; Inaba K; Kumano M; Yoshikawa N; Yoshioka Y; Nakamura K; Hiratsuka J; Itami J; Hayakawa K
    Brachytherapy; 2017; 16(3):503-510. PubMed ID: 28222973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
    Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
    Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
    Baumann BC; Baumann JC; Christodouleas JP; Soffen E
    Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy.
    Tward JD; O'Neil B; Boucher K; Kokeny K; Lowrance WT; Lloyd S; Cannon D; Stephenson RA; Agarwal N; Farr T; Petragallo R; Sherar NZ; Kunz I; Hofer A; Courdy S; Shrieve DC; Dechet C
    Clin Genitourin Cancer; 2020 Aug; 18(4):274-283.e5. PubMed ID: 32335059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abdominoperineal resection for rectal cancer at a specialty center.
    Nissan A; Guillem JG; Paty PB; Douglas Wong W; Minsky B; Saltz L; Cohen AM
    Dis Colon Rectum; 2001 Jan; 44(1):27-35; discussion 35-6. PubMed ID: 11805560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer.
    Lilleby W; Tafjord G; Raabe NK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):933-9. PubMed ID: 22138456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
    Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
    Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer.
    Fischer-Valuck BW; Rao YJ; Brenneman RJ; Patel PR; Filson CP; Jani AB; Liu Y; Goyal S; Xu K; Weiss A; Kucuk O; Cimmino C; Szabo S; Rossi P; Baumann BC; Pattaras J; Hershatter B; Patel SA
    Brachytherapy; 2020; 19(5):557-566. PubMed ID: 32624405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety and prognosis analysis of transanal total mesorectal excision versus laparoscopic mesorectal excision for mid-low rectal cancer].
    Sun R; Cong L; Qiu HZ; Lin GL; Wu B; Niu BZ; Sun XY; Zhou JL; Xu L; Lu JY; Xiao Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):522-530. PubMed ID: 35754217
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer.
    Madbouly KM; Hussein AM; Abdelzaher E
    Am J Surg; 2014 Sep; 208(3):332-41. PubMed ID: 24581995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can increasing the dose of radiation by HDR brachytherapy boost following pre operative chemoradiotherapy for advanced rectal cancer improve surgical outcomes?
    Sun Myint A; Mukhopadhyay T; Ramani VS; Perkins K; Snee AJ; Jelley F; Wong H; Lee CD
    Colorectal Dis; 2010 Aug; 12 Suppl 2():30-6. PubMed ID: 20618365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.